Abstract
We present, for the first time to our knowledge, a patient with Systemic Lupus Erythematosus (SLE) with pulmonary Bronchial-Associated Lymphoid Tissue (BALT) lymphoma, refractory to chemotherapy but after a single four-week course of rituximab experienced significant regression of pulmonary lesions and remained progressionfree six months post- treatment. This case report demonstrates the promising role for rituximab in refractory BALT lymphoma.
Highlights
Marginal zone lymphomas arise from memory B cells in the marginal zone of lymphoid tissue [1]
Post-rituximab b d c most common type of primary pulmonary lymphoma is the extranodal marginal zone B-cell lymphoma of Mucosa Associated Lymphoid Tissue (MALT) type, which arises from Bronchus-Associated Lymphoid Tissue (BALT) [15]
The possible hypothesis behind Bronchial-Associated Lymphoid Tissue (BALT) lymphoma is the repeated infections leading to persistent antigen-stimulation, chronic inflammation, and uncontrolled B-cell proliferation, resulting in development of BALT lymphoma
Summary
Marginal zone lymphomas arise from memory B cells in the marginal zone of lymphoid tissue [1]. It has been speculated that pulmonary MALT lymphomas might develop secondary to chronic antigenic stimulation of the lungs from long-term exposure to smoking, infections, or autoimmune diseases [5,6]. Few short series and single case reports showed that rituximab as a single agent or as an adjunct to other therapy is safe, with significant activity in untreated or relapsed BALT lymphoma patients [5,10,11,12,13,14,15,16].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
